Mediwound Ltd (NASDAQ:MDWD), a fully-integrated biopharmaceutical company developing, manufacturing and commercializing innovative therapies to address unmet needs in severe burn and wound management, today announced the closing of its initial public offering of 5,750,000 ordinary shares at a price to the public of $14.00 per share. All of the shares of common stock in the offering were offered by MediWound and include 750,000 shares issued pursuant to the full exercise of the underwriters’ 30-day option to purchase up to 750,000 additional shares at the initial public offering price. Mediwound Ltd (NASDAQ:MDWD) shares after opening at $13.78 moved to $14.00 on last trade day and at the end of the day closed at $12.80. Price to cash ratio as 27.13.Mediwound Ltd (NASDAQ:MDWD) showed a negative weekly performance of -15.23%.
Sorrento Therapeutics Inc (NASDAQ:SRNE), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, announced today that it will present data on the comparison of Cynviloq™ and Abraxane® (nab-paclitaxel) pharmacokinetics (PK) from animal studies. The PK data will be presented by Dr. Kouros Motamed, Vice President of Clinical Development & Nanomedicine on April 9 from8:00 AM to 12:00 PM in Hall A-E, poster session 28 at San Diego Convention Center, entitled: “IG-001—Potential as Intraperitoneal Therapy for Ovarian Cancer. Sorrento Therapeutics Inc (NASDAQ:SRNE) shares fell -10.14% in last trading session and ended the day on $11.26. SRNE return on equity ratio is recorded as -112.80% and its return on assets is -92.60%. Sorrento Therapeutics Inc (NASDAQ:SRNE) yearly performance is 125.20%.
Anacor Pharmaceuticals Inc (NASDAQ:ANAC) enrolled the first patient in a phase III study on its atopic dermatitis candidate, AN2728, for the topical treatment of mild-to-moderate atopic dermatitis.The phase III trials comprise two multi-center, double-blind, randomized (2:1), placebo-controlled studies enrolling roughly 750 patients (two years and above) each. Anacor Pharmaceuticals Inc (NASDAQ:ANAC) shares moved down -10.45% in last trading session and was closed at $17.06, while trading in range of $16.99-$19.28. Anacor Pharmaceuticals Inc (NASDAQ:ANAC) year to date performance is 1.67%.
Enanta Pharmaceuticals (NASDAQ:ENTA) Insider Yat Sun Or sold 10,000 shares of the stock on the open market in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $39.16, for a total transaction of $391,600.00. Following the completion of the sale, the insider now directly owns 189,078 shares in the company, valued at approximately $7,404,294. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.Enanta Pharmaceuticals Inc (NASDAQ:ENTA) weekly performance is -10.51%. On last trading day company shares ended up $34.47. Enanta Pharmaceuticals Inc (NASDAQ:ENTA) distance from 50-day simple moving average is -8.87%. Analysts mean target price for the company is $44.80.